The Myelin Repair Foundation's Accelerated Research Collaboration™ (ARC™) model is bringing about a sea change in the way all medical research is done. This is the only way to ensure that promising research results in real patient treatments – in the shortest amount of time. We are demonstrating the ARC model in a research program for developing the next generation treatment for multiple sclerosis—myelin repair.
An Integrated Model = Accelerated Research = New Treatment or Cure
MRF is the only research organization that addresses every phase in the drug discovery process, from initial research all the way to licensing by commercial drug developers.
Through ongoing management oversight, the development of new research tools and strategic relationship building, the Accelerated Research Collaboration™ (ARC™) model optimizes and integrates the contributions of all those who participate in the value chain of making new medicines.
As a result the ARC model
- Provides a larger number of therapeutically relevant treatment targets in the pipeline
- Translates discoveries made in animal models to the human system
- Builds partnerships with pharmaceutical companies to develop and bring new drugs to market and
- Ultimately, improves quality of life for millions living with diseases for which there are currently no effective treatment or cures.
So far, our results have been stunning.
Read more about how the ARC model has accelerated research in myelin repair.
Why Change is Needed
As David Bornstein stated in a recent New York Times article: “An ocean of research is producing cures and treatments by the drop.”
In the last decade, in spite of a doubling of dollars invested in academic research and commercial research and development, the number of new drugs coming to market has remained flat.
The Myelin Repair Foundation is changing this with a new model that promises to speed treatments. Read about how our model is accelerating myelin repair research.
Make a Donation
Your gift today will help us reach the first myelin repair Phase I Clinical Trial by 2014.
